Skip to main content

Advertisement

Table 1 Patients’ demographic and clinical characteristics

From: Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?

  Group A (SST) n = 100 Group B (LST) n = 100 p
Mean age (years) 52.4 ± 16.2 (range 18–89) 54 ± 15.3 (range 18–81) 0.458
Gender
 - Female  - Male 55% 45% 60% 40% 0.567
Smoking habits 8% 8% 1
Alcohol consumption 19% 10% 0.107
Indication(s) for H. pylori eradication
 - Non-ulcer dyspepsia  - Peptic ulcer  - GERD/chronic use of PPI  - Before bariatric surgery  - Anemia or thrombocytopenia  - Familial history of gastric cancer 63% 14% 11% 9% 2% 1% 72% 10% 11% --- 7% --- 0.307 0.452 1 --- 0.229 ---
Nitroimidazole antibiotic
 - Tinidazole  - Metronidazole 53% 47% 81% 19% 0.001
Metronidazole dosage
 - 500 mg 12–12 h (1000 mg)  - 500 mg 8–8 h (1500 mg) 29,8% 70,2% 21,1% 79,9% 0.554
PPI 1st or 2nd generation
 - Omeprazole / Pantoprazole / Lansoprazole  - Esomeprazole / Rabeprazole 81% 19% 89% 11% 0.165
PPI dosage
 - Full-dose  - Half-dose 91% 9% 88% 12% 0.645
Prescribing Physician
 - Gastroenterologist  - Non-Gastroenterologist 79% 21% 94% 6% 0.002
  1. SST standard sequential treatment, LST levofloxacin-based sequential treatment, GERD gastroesophageal reflux disease, PPI proton-pump inhibitor